Clinical Trials Directory

Trials / Terminated

TerminatedNCT00162695

Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
400 (planned)
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
Sex
All
Age
6 Months – 21 Years
Healthy volunteers
Not accepted

Summary

Objective of the study objectives was to explore survival advantage for an intensified chemotherapy strategy in a randomised trial. IVA (ifosfamide, vincristine, actinomycin D) or a 6 drug combination (IVA + carboplatin, epirubicin, etoposide) both delivered over 27 weeks. Cumulative dose / m2 = ifosfamide 54g (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug). Delivery of radiotherapy was determined according to site and / or response to chemotherapy ± surgery. The study was powered to detect 10% difference in 3 year OS.

Conditions

Interventions

TypeNameDescription
DRUGIfosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide

Timeline

Start date
1995-07-01
First posted
2005-09-13
Last updated
2005-09-13

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00162695. Inclusion in this directory is not an endorsement.